Biotech Market Spotlight: HealthLinx
Wednesday, 24 February, 2010
UPDATED: Victorian biomarker and diagnostic company, HealthLinx (ASX:HTX), has seen its share price bounce by over 110% in afternoon trading, up 9.3c to 17.5c on the back of news that its ovarian cancer diagnostic product, OvPlex, will be marketed in the United Kingdom by distribution partner, Intus Healthcare.
According to a company release, the market size is in excess of three quarters of a million units per year, with HealthLink receiving around $70 royalty per unit, depending on exchange rates.
In July 2009 the company obtained European Certification for OvPlex paving the way to market and sell the product within the European community.
Intus Healthcare reached an exclusive distribution agreement with HealthLinx in February 2009 for distribution of OvPlex in the UK and Republic of Ireland (ROI) with an option to enter other EU countries.
The promotion of OvPlex is supported by the Spire Healthcare network of 36 hospitals that have multiple pathology operations in the UK. Women can now order the OvPlex test directly from Intus Healthcare (web site Ovplex.co.uk) and visit a Spire location closest to them, where a small blood sample will be taken. The cost of an OvPlex test will be £275 (incl. VAT).
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
